EpithalonvsHumanin

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on epithalamin, a peptide extract from the pineal gland first studied by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary reported mechanism is the activation of telomerase — the ribonucleoprotein enzyme complex responsible for maintaining telomere length at chromosome ends.

Telomeres are repetitive nucleotide sequences (TTAGGG in humans) that cap and protect chromosome ends from degradation, fusion, and recognition as DNA damage. With each cell division, the DNA replication machinery cannot fully copy the very end of the lagging strand (the 'end replication problem'), resulting in progressive telomere shortening. When telomeres reach a critical length, cells enter replicative senescence (permanent growth arrest) or apoptosis — a fundamental mechanism of cellular aging. Telomerase, composed of the catalytic subunit hTERT (human telomerase reverse transcriptase) and the RNA template component hTR/TERC, can add TTAGGG repeats back to chromosome ends, counteracting this shortening.

Epithalon reportedly activates the expression of the hTERT gene, increasing telomerase activity in somatic cells. In cell culture studies, epithalon treatment was associated with increased telomere length and extended replicative lifespan in human fibroblasts and retinal pigment epithelial cells. The peptide also reportedly stimulates melatonin production by the pineal gland, potentially through gene-regulatory effects on pineal cells. Melatonin itself is a potent antioxidant and circadian regulator, and its decline with age correlates with numerous age-related changes. Additional reported effects include normalization of T-cell function, modulation of neuroendocrine signaling, and improved antioxidant enzyme expression. It should be noted that the majority of published research comes from Russian institutions, and large-scale, peer-reviewed Western clinical trials are lacking.

Humanin is a 24-amino-acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA) encoded within the 16S ribosomal RNA gene of the mitochondrial genome. Its discovery in 2001 was revolutionary — it was the first identified mitochondrial-derived peptide (MDP), challenging the long-held dogma that the mitochondrial genome only encodes 13 oxidative phosphorylation subunits, 22 tRNAs, and 2 rRNAs. Humanin, along with MOTS-C and the SHLP peptides discovered later, established mitochondria as endocrine organelles.

Humanin exerts cytoprotective effects through multiple mechanisms. Extracellularly, it binds to a trimeric receptor complex composed of CNTFR (ciliary neurotrophic factor receptor alpha), WSX-1 (IL-27 receptor alpha), and gp130 (the shared signaling subunit of the IL-6 receptor family). Activation of this complex triggers JAK/STAT3 signaling, which drives expression of anti-apoptotic genes (Bcl-2, Mcl-1) and cell survival programs. Intracellularly, humanin interacts directly with two pro-apoptotic proteins: it binds IGFBP-3, preventing IGFBP-3 from translocating to mitochondria and initiating apoptosis; and it binds BAX (Bcl-2-associated X protein), preventing BAX oligomerization and insertion into the outer mitochondrial membrane — the critical step in the intrinsic (mitochondrial) apoptosis pathway that releases cytochrome c and activates caspases.

Humanin also reduces cellular stress through multiple pathways. It decreases reactive oxygen species (ROS) production by optimizing mitochondrial electron transport chain function. It reduces endoplasmic reticulum (ER) stress by modulating the unfolded protein response (UPR). It improves insulin sensitivity through STAT3-mediated effects on hypothalamic signaling and peripheral insulin receptor substrate phosphorylation. Circulating humanin levels decline with age (approximately 40% reduction between youth and old age) and are inversely correlated with markers of age-related disease, suggesting that humanin decline contributes to the increased cellular vulnerability and apoptosis susceptibility seen in aging. Its most potent synthetic analogue, HNG (S14G-humanin), has a glycine-for-serine substitution at position 14 that increases cytoprotective potency approximately 1,000-fold.